Clinical studies recruiting near Kyoto

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Observational Study Protocol: LIVER-R
Phase N/A · Research Site · AstraZeneca · NCT06252753 A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · Kyoto University Hospital · Eli Lilly and Company · NCT07218380 Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
Phase 3 · Japanese Red Cross Kyoto Daini Hospital · Joseph Broderick, MD · NCT07227246 Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Phase 3 · Kyoto Prefectural University of Medicine · Princess Maxima Center for Pediatric Oncology · NCT05327894 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Kyoto University Hospital ( Site 3415) · Merck Sharp & Dohme LLC · NCT06393374 Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
Phase 2 · Kyoto University Hospital · Kyoto University Hospital · NCT05879653 This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · National Hospital Organization Kyoto Medical Center · Pfizer · NCT06758401 Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Phase 1/Phase 2 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06704269 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Rakuwakai Otowa Hospital · Amgen · NCT07037433 Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Phase 4 · Research Site · Alexion Pharmaceuticals, Inc. · NCT07308574 A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06581198 Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · University Hospital,Kyoto Prefectural University of Medicine · Eli Lilly and Company · NCT06890598 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · Research Site · AstraZeneca · NCT06868277 A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · National Hospital Organization Kyoto Medical Center · Pfizer · NCT07144280 EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Phase 3 · Kyoto University Hospital · Boehringer Ingelheim · NCT06531824 Pilot Study: Effects of CCP Intervention on NICU Environment and Preterm Infants Development
NA · Kyoto University Hospital · Turku University Hospital · NCT07306000 A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours
Phase 1 · Kyoto University Hospital · Ipsen · NCT07441707 Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor
Phase 2 · Kyoto University Hospital ( Site 1806) · Merck Sharp & Dohme LLC · NCT04924075 A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Phase 1 · Kyoto University Hospital · Eli Lilly and Company · NCT07114601 Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
Phase 2 · University Hospital Kyoto Prefectural University of Medicine · National Cancer Center, Japan · NCT06673628 A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Phase 3 · University Hospital,Kyoto Prefectural University of Medicine · Eli Lilly and Company · NCT06672549 Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome
Phase 3 · University Hospital,Kyoto Prefectural University of Medicine · Shoichi Maruyama MD PhD · NCT05914155 A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Ad
Phase 2 · Kyoto University Hospital /ID# 276398 · AbbVie · NCT07196644 A Study of ZW251 in Participants With Advanced Solid Tumors
Phase 1 · Kyoto University Hospital · Zymeworks BC Inc. · NCT07164313 ONO-4538 Study in Patients With Richter's Transformation
Phase 2 · Kyoto University Hospital · Ono Pharmaceutical Co., Ltd. · NCT06936943 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · Research Site · AstraZeneca · NCT06692738 Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed
Phase 2 · University Hospital,Kyoto Prefectural University of Medicine · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06297226 Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of
Phase 3 · Research Site · AstraZeneca · NCT06921785 A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not
Phase 3 · FIN-57001, Kyoto, Kyoto · Colorado Prevention Center · NCT06033950 SMP-3124LP in Adults With Advanced Solid Tumors
Phase 1/Phase 2 · Kyoto University Hospital · Sumitomo Pharma America, Inc. · NCT06526819

Look up another city

Look up another condition